Why Insmed Incorporated (INSM) stock moved
Insmed Incorporated (INSM) shares rose 2.8% to $134.75 as of August 10, 2026, a moderate gain from the prior close of $131.10. BestStocks flagged the session as a major change for INSM. Below, we break down what changed for INSM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
INSM climbed 2.8% to $134.75
Insmed surged 2.58% to $134.48 following a Q2 2026 earnings beat released pre-market, with total revenue of $425.5 million crushing analyst consensus (~$390 million) and its flagship rare lung disease drug Brinsupri posting $309.2 million in sales—a 49% sequential jump. Management simultaneously raised full-year Brinsupri revenue guidance to $1.25–$1.40 billion (from $1.0 billion) and lifted peak sales projections above $7 billion, while narrowing the net loss to $0.06 per share versus an expected $0.70 loss. Analyst consensus revisions and price-target updates in response to the raised full-year guidance; tracking whether Brinsupri maintains sequential growth momentum in Q3 2026.
What it means for Insmed Incorporated investors
For Insmed Incorporated investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 2.8% session move. Weighing against that: Insmed Incorporated (INSM) moved -2.89% from $135.00 to $131.10 on 2026-08-07; Insmed Incorporated (INSM) moved -2.59% from $109.47 to $106.64 on 2026-07-22. Wall Street's consensus price target sits at $197.43, implying +46.5% upside from $134.75. BestStocks rates the overall signal quality low (47/100). With earnings roughly 80 days out, the next report is the most likely near-term test of the move.
INSM price reaction
INSM last traded at $134.75, up $3.65 (+2.78%) from the previous close of $131.10. The session traded on 1.0× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $98.45 and $134.75, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Insmed Incorporated (INSM)
The consensus analyst price target on Insmed Incorporated (INSM) is $197.43, 46.5% above the recent $134.75. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on INSM line up.
The bullish case
- Wall Street's consensus price target of $197.43 implies +46.5% upside from $134.75.
- The Street's most bullish target is $235.00 (+74.4%).
- Material positive event.
- Positive 2.8% session move.
- INSM moved +3.38% from its $128.22 open to a $132.55 close on 2026-08-06.
The bearish case
- Insmed Incorporated (INSM) moved -2.89% from $135.00 to $131.10 on 2026-08-07.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 10, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for INSM
Frequently asked questions about INSM
Why did Insmed Incorporated (INSM) stock move?
INSM rose 2.8% to $134.75. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did INSM stock rise?
INSM gained 2.78% ($3.65) versus the prior close of $131.10, last trading at $134.75 on 1.0× average volume.
When is Insmed Incorporated's next earnings date?
INSM's next earnings report is estimated for 2026-10-29 — about 80 days away.
What is the analyst price target for INSM?
The consensus analyst price target for INSM is $197.43, about 46.5% above the current $134.75. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks INSM
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared INSM-specific materiality thresholds, triggering an evidence check. It draws on 18 tracked change events for INSM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 10, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.